Case Report
Open Access

Placental Mesenchymal Dysplasia: Report of A Case and Review of the Literature

Stefania Erra*, Alessia Frigeri, Alessia Picozzi

Surgical Pathology Department, Santo Spirito Hospital, Casale Monferrato, Italy

*Corresponding Author: Stefania Erra, Surgical Pathology Department, Santo Spirito Hospital, Casale Monferrato, Italy, Tel: 00390142434894; E-Mail:

Received: 22 January 2018; Accepted: 01 February 2018; Published: 05 February 2018


Vascular abnormality; Placenta; Pathologic placenta

Untitled Document


The PMD is a rare vascular abnormality of the placenta, with an incidence of 0.02%. Macroscopically, the placenta is macrosomic and thickened, with dilated sub-chorionic vessels and anomalous anastomoses. Placental weight can be over 1000 gr at the end of the pregnancy. This pathology was first reported by Moscoso in 1991 [1]. He described an enlarged placenta with widespead villus hyperplasia of the peduncle and increased levels of ?-fetoprotein in blood. Vessels on the fetal plate showed aneurysmal and varicose dilatations, and the stem villi appeared as semitranslucent lobulated structures. At the microscopy level, this pathologic placenta presented excessive proliferation of mesenchymatous tissue with foci of myxoid degeneration with none pathological trophoblastic proliferation. Placenta with PMD morphology can have a normal karyotype or it may be associated with chromosomal abnormality. In 23% of cases, PMD is linked to Beckwith-Wiedemann Syndrome (BWS), suggesting a common genetic alteration [2]. It has been described a spectrum of phenotypic variations in PMD, sometimes limited only to the placenta, many times involving both fetus and placenta. In these last cases, abnormal expression of one or more genes on chromosome 11 has been observed, above all in the region 11p15.5 [3]. The PMD diagnostic suspect is based on detection of ultrasound with diffuse cystic aspect of the placenta, with image suggested for molar degeneration (80% of cases) and placentomegalia (50% of cases). Placental mesenchymal dysplasia is associated with intrauterine growth restriction or intrauterine fetal death in the third trimester of gestation, even in the absence of fetal malformations.

Keywords: Vascular abnormality; Placenta; Pathologic placenta

1. Case Report
Placenta at the 30th week of pregnancy of a first child 30 year old Indian woman was send in the surgical pathology department for macroscopic aberrant vascular alterations and high weight, precisely 1700 grams (Figure 1). It presented a segment of umbilical cord with velamentous insertion. The chorionic plate, size 23 × 22 × 7 cm, was characterized by sub-chorionic vessels markedly swollen and arborescent aspect, anastomosed in a tangle of subverted and unrecognizable structures similar to cysts (Figure 2 and 3).


Figure 1: Placenta specimen with placentomegaly.


Figure 2: Detailed gross vessels of placenta.


Figure 3: Cyst-like aspect of sub-decidual placental vessels.

Microscopically, the chorionic plate presented thinning of the terminal villi, presence of large caliber stem ones, with fibrotic and edematous stroma, marked dilatation of the vessels with hamartomatous appearance (Figure 4 and 5). There were also areas of hemorrhagic and ischemic infarction associated with thrombotic occlusion of some structures. In addition, acute granulocytic inflammation was found on decidua and funiculus. At birth, the female newborn weighed 2400 grams and had no obvious malformations. She was admitted to neonatal intensive care for presumably respiratory problems related to funisitis. No genetic examination was performed on the placenta and the newborn for economic reasons, since the mother was unable to bear the costs of such diagnostic investigations.


Figure 4: E.E slide with gross anomalous stem villi (4x).


Figure 5: E.E. slide representing abnormal structure of chorionic plate without well-formed intermediate and terminal villi.

2. Discussion
PMD is a rare condition linked to chromosomal aberrations. The 33% of fetus with PMD is affected by Intra Uterine Growth Retard (IUGR), the 38% by fetal malformations and the 13% by fetal stillbirth in extreme cases [4, 5]. In 9% of cases, maternal complications have been reported: preeclampsia (single or in combination, presence of edema, proteinuria, hypertension), eclampsia with gestational hypertension, HELLP Syndrome (hemolysis, elevated liver enzymes, thrombocytopenia). Finally, in 23% of cases the PMD is associated with Beckwith-Wiedemann Syndrome, suggesting a common genetic bases involving the abnormal expression of one or more genes on chromosome 11.

As regards the origin of this placental anomaly, one of the most reliable hypothesis suggests that PMD occurs when 1 ovum is fertilized by 2 spermatozoa with errors during the first meiotic division of the fertilized egg cell [5]. These errors could be responsible of silencing or disruption of the imprinted genes that regulate normal placental formation, with resulting in aberrant growth of placental tissue and placentomegaly [6]. Only 110 cases of PMD have been reported in literature in an article dated 2014 [7], while not more than 10 cases have been described after this date. Despite everything, the mesenchymal dysplasia of the placenta constitutes an underestimated diagnostic entity, because early cases can be confused with a partial hydatidiform mole, above all in abortions of the first trimester of gestation for the similar sonographic findings of the two entities.

The vesicular mole is characterized by the presence of swelling and abnormal stem villi, with trophoblastic alterations and without the net of little vessels normally located in villous stroma. Hydatidiform mole is a gestational trophoblastic disease linked to chromosomal aberrations of the product of conception and incompatible with the life of the fetus. It becomes important the correct differential diagnosis between these two entities with similar morphology but different outcomes. In fact, in PMD there usually can be observed caryotypically and morphological normal fetus and a good maternal-fetal outcome [8], as in the present reported case. An exception is represented by the relatively frequent presence of BWS associated with PMD, which can be recognized through study of the karyotype with CGH-Array [2, 3].

The BWS is a pan-ethnic disease, with an estimated prevalence of 1 out of 13700; the incidence is equal in both sexes. Patients affected by BWS show overgrowth in the second half of pregnancy and in the first years of life; in addition to this it can be observed macrosomia, macroglossia, hemihyperthrophy, omphalocele, embryonic tumors, visceromegaly , cleft palate and cardiomyopathy.

The BWS is due to genetic and/or epigenetic alterations that modify the function, genes undergo imprinting on chromosome 11p15.5. The disease is sporadic in 85% of cases, while in other cases there is a familiar transmission. Both the PMD and the BWS are related to the abnormal expression of one or more genes on chromosome 11. In the light of what is reported, it is not explained how the presence of a chromosomal alteration established at the beginning of pregnancy can determine PMD without repercussions on the fetus. Most cases of PMD are, in fact, described in fetuses of the last trimester of gestation without chromosomal alterations. In such cases endouterine death or IUGR are caused by vascular insufficiency of the placenta with PMD.

3. Conclusion
PMD is a rare disease affecting placenta and it is linked to mutations of chromosome 11. Most of cases are reported in cariotypically normal fetuses, with IUGR or fetal intrauterine death. The most important differential diagnosis must be made with the molar pathology of the trophoblast. In fact, hydatiforme mole represents a gestational trophoblastic disease due to chromosomal aberrations affecting fetus too. This differential diagnosis can’t be made only on the basis of clinical and ultrasound data, so pathologists make the correct diagnosis on the placenta after the birth. For this reason it is essential to consider that the PMD can have morphological characteristics that are not always pathognomonic, even if peculiar. Consequently, it is important that pathologists take this diagnostic entity into consideration in the presence of a placenta with a weight much higher than normal and with an abnormal vascularization, consisting of dilateted and arborescent vessels, sometimes of a cyst-like appearance.

In case of suspected diagnosis, it can be performed fetal karyotype, ?-fetoprotein dosage, careful study to search for signs of BWS and in particular to exclude liver tumors, serial ultrasounds and histological examination of the placenta. Many children with PMD don’t suffer from malformative defects, but the prognosis poses the risk of early death from secondary complications to hypoglycemia, prematurity or cardiomyopathy. In patients who survive infancy, the prognosis is generally good. In PMD genetic counseling is always recommended, even if a hereditary transmission of the chromosomal defect has not been described.

Finally, we need to remember the usefulness of a comprehensive macroscopic sampling of placenta in case of suspected mesenchymal dysplasia and the possibility of using ancillary methods to histology. About that immunohistochemical research of p57 protein expression represents a simple but important one, because in stromal cells of dysplastic stem villi in all cases of PMD a loss of p57 expression can be detected [9, 10].


  1. Moscoso G, Jauniaux E, Hustin J. Placental vascular anomaly with diffuse mesenchymal stem villous hyperplasia. A new clinic-pathological entity? Pathol Res Pract 187 (1991): 324-328.
  2. H’mida D, Gribaa M, Yacoubi T, et al. Placental mesenchymal dysplasia with Beck-Wiedemann syndrome fetus in the context of biparental and androgenic cell lines. Placenta 29 (2008): 454-460.
  3. Robinson WP, Slee J, Smith N, et al. Placental mesenchymal dysplasia associated with fetal overgrowth and mosaic deletion of the maternal copy of 11p15.5. Am J Med Genet A 143A (2007): 1752-1759.
  4. Pham T, Steele J, Stayboldt C, et al. Placental mesenchymal dysplasia is associated with high rates of intrauterine growth restrictions and fetal demise: a report of 11 new cases and a review of the literature. Am J Clin Pathol 126 (2006): 67-78.
  5. Nogba Pawoo DO, Heller DS. Placental Mesenchymal Dysplasia Arch Pathol Lab Med 138 (2014): 1247-1249.
  6. Surti U, Yatsenko S, Hu J, et al. Maternal GRB10 microdeletion is a novel cause of cystic placenta: Spectrum of genomic changes in the etiology of enlarged cystic placenta. Placenta 57 (2017): 33-41.
  7. Toscano MP, Schultz R. Placental mesenchymal dysplasia: case report with gross and histological findings Autopsy and Case Reports 4 (2014): 51-56.
  8. Gizzo S, Di Gangi S, Patrelli TS, et al. Placental mesenchymal dysplasia: Can early diagnosis ensure a good materno-foetal outcome? A case report. Arch Gynecol Obstet 286 (2012): 15-17.
  9. Allias F, Lebreton F, Collardeau-Frachon S, et al. Immunohistochemical expression of p57 in placental vascular proliferative disorders of preterm and term placentas. Fetal Pediatr Pathol 28 (2009): 9-23.
  10. Chilosi M, Piazzola E, Lestani M, et al. Differential expression of p57kip2, a maternally imprinted cdk inhibitor, in normal human placenta and gestational trophoblastic disease. Lab Invest 78 (1998): 269-276.